HAMBURG, Germany, March 25, 2015 /PRNewswire/ -- Omnicell, Inc.,
(NASDAQ: OMCL) will exhibit the integration of its automated
medication cabinets with MACH4's modular robotic solutions at the
European Association of Hospital Pharmacists (EAHP) 25-27
March. Omnicell recently announced its agreement to purchase
MACH4 Pharma Systems and the EAHP Congress will be the first event
to highlight the full spectrum of medication products that Omnicell
will be able to offer for the hospital, community and home
settings, pending completion of Omnicell's acquisition of MACH4
Pharma Systems.
MACH4's modular robotic solutions allow for dispensing
medications in original manufacturers' packages and complement the
innovative software capabilities of Omnicell dispensing
systems. The joint Omnicell/MACH4 exhibit will feature the
MACH4 robotic medication management systems integrated with the
Omnicell automated dispensing cabinet and Savvy mobile medication
workstation. Omnicell's medication adherence packaging
solutions will also be showcased. These innovative solutions span
the continuum of care to help meet the unique demands of Omnicell's
growing customer base worldwide.
One of the hospitals currently using the integrated medication
automation is St. Mary's Hospital, the main facility of the Isle of
Wight NHS Trust. St. Mary's is the only fully integrated provider
in England for acute hospital,
community, mental health and ambulance services and is using
Omnicell medication management systems in all care areas of the
hospital. Omnicell's medication cabinets are automatically
refilled through integration with the MACH4 robotic dispensing
system, which is based in the hospital pharmacy.
"This fully integrated solution, supported by a grant from the
NHSE Technology Fund, helps to increase efficiency and improve
patient safety of ward based dispensing," said Gillian Honeywell, chief pharmacist at St.
Mary's hospital. "The integration of Omnicell and MACH4 has
significantly reduced data entry and eliminated errors in ward
stock replenishment. The time savings for pharmacy and nursing
with this integration has been tremendous. We have completely
changed the way we work – within weeks of installing the MACH4
robot integrated with the Omnicell medication dispensing system and
our electronic prescribing system, we were able to allocate more
staff time on wards caring for patients," Honeywell added.
Also during the conference Omnicell will co-sponsor, along with
its UK supplier, Avantec, a satellite symposium titled "Omnicell –
Closing the Loop in Medicines Administration". This symposium will
be held Thursday 26 March from 15:00 – 16:30 in Hall 4 of the CCH -
Congress Center Hamburg.
"We are very excited to introduce the European market to this
example of the integration of Omnicell dispensing cabinets with the
MACH4 robot," said Arthur Van
Dongen, vice president and general manager, EMEA for
Omnicell. "It is anticipated that Omnicell's acquisition
of MACH4 would result in a fully integrated solution for
pharmacy and nursing, and provide significant benefits in
the medication dispensing processes by helping to improve
efficiency, accuracy and patient safety. We are proud to
provide solutions that echo the EAHP 2015 programme, which is
organized around the topic the hospital pharmacist's agenda –
patient safety first."
Please visit the Omnicell/MACH4 stand 102 during EAHP 2015
About Omnicell
Since 1992, Omnicell (NASDAQ: OMCL) has been creating new
efficiencies to improve patient care, anywhere it is delivered.
Omnicell is a leading supplier of comprehensive automation and
business analytics software for patient-centric medication and
supply management across the entire health care continuum—from the
acute care hospital setting to post-acute skilled nursing and
long-term care facilities to the home.
More than 3,000 customers worldwide have utilized Omnicell
Automation and Analytics solutions to increase operational
efficiency, reduce errors, deliver actionable intelligence and
improve patient safety. Omnicell Medication Adherence solutions,
including its MTS Medication Technologies brand, provide innovative
medication adherence packaging solutions to help reduce costly
hospital readmissions. In addition, these solutions enable
approximately 6,000 institutional and retail pharmacies worldwide
to maintain high accuracy and quality standards in medication
dispensing and administration while optimizing productivity and
controlling costs.
For more information about Omnicell, Inc. please visit
www.omnicell.com.
"Safe Harbor" Statement under the Private Securities
Litigation Reform Act of 1995
This press release contains forward-looking statements,
including, but not limited to, statements related to the
anticipated consummation of the acquisition of MACH4 Pharma Systems
and the benefits thereof, including the integration of Omnicell's
and MACH4's and the anticipated benefits thereof, including,
increased efficiency, accuracy and patient safety. These
forward-looking statements are based on Omnicell's current
expectations and inherently involve significant risks and
uncertainties. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which
include, without limitation, risks related to Omnicell's ability to
complete the acquisition on the proposed terms and schedule,
including risks and uncertainties related to the satisfaction of
closing conditions, including, but not limited to risks associated
with business combination transactions, such as the risk that
acquired business will not be integrated successfully or that such
integration may be more difficult, time-consuming or costly than
expected; risks related to future opportunities and plans for the
combined company, including the reaction of the combined company's
customers and potential customers, the perceived complementary
nature of the combined company's products and solutions,
uncertainty of the expected financial performance, market
opportunities and results of the combined company following
completion of the proposed acquisition; and the possibility that if
Omnicell does not achieve the perceived benefits of the proposed
acquisition of MACH4 as rapidly or to the extent anticipated by
financial analysts or investors, the market price of Omnicell stock
could decline; as well as other risks related Omnicell's business,
and those other risks detailed from time to time under the caption
"Risk Factors" and elsewhere in Omnicell's SEC filings and reports,
including in the Annual Report on Form 10-K for the year ended
December 31, 2013 and Quarterly
Report on Form 10-Q for the quarter ended September 30, 2014. Omnicell undertakes no duty
or obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or
changes in its expectations.
OMCL-G
Editor's Notes:
- All Omnicell news releases (financial, acquisitions, products,
technology etc.) are issued exclusively by PR Newswire and are
immediately thereafter posted on the company's external website,
omnicell.com.
- Omnicell and the Omnicell logo design are registered trademarks
of Omnicell, Inc. All other brand or product names may be
trademarks or registered trademarks of their respective
companies.
Logo -
http://photos.prnewswire.com/prnh/20120731/SF48971LOGO-a
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/omnicell-to-present-expanded-medication-management-integration-at-the-european-association-of-hospital-pharmacists-congress-300055129.html
SOURCE Omnicell, Inc.